FY2025 EPS Estimates for Biogen Lowered by Cantor Fitzgerald

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Biogen in a research report issued on Thursday, February 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company will post earnings per share of $16.13 for the year, down from their prior estimate of $17.04. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%.

A number of other brokerages also recently issued reports on BIIB. Oppenheimer lowered their price target on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. BMO Capital Markets lowered their price objective on shares of Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a report on Thursday. TD Cowen decreased their price target on Biogen from $300.00 to $275.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. StockNews.com cut Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 28th. Finally, Wolfe Research initiated coverage on shares of Biogen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $211.96.

Biogen Trading Down 0.8 %

NASDAQ:BIIB opened at $137.33 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. Biogen has a 1 year low of $128.51 and a 1 year high of $238.00. The company has a market cap of $20.01 billion, a P/E ratio of 12.41, a P/E/G ratio of 1.65 and a beta of -0.08. The stock’s fifty day moving average price is $146.90 and its two-hundred day moving average price is $173.26.

Institutional Investors Weigh In On Biogen

A number of large investors have recently made changes to their positions in the company. Larson Financial Group LLC increased its holdings in Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 141 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in Biogen during the fourth quarter worth approximately $25,000. OFI Invest Asset Management purchased a new stake in shares of Biogen in the fourth quarter valued at $32,000. Ashton Thomas Securities LLC bought a new stake in Biogen in the third quarter worth about $33,000. Finally, SRS Capital Advisors Inc. bought a new position in Biogen in the 4th quarter valued at $33,000. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.